Evidence map›Paper›PMID 40748075›Full record

ReviewJournal of bacteriology2025

Extracellular defense of bacteria against antimicrobial peptides.

Osmel Fleitas, Eria A Rebollar, Víctor H Bustamante

Abstract readReview
In one paragraph

Review in Journal of bacteriology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Interactions ofInternational journal of molecular sciences · 2025
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Osmel FleitasDepartamento de Microbiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.ORCID 0000-0001-7505-6146
Eria A RebollarPrograma de Microbiología Genómica, Centro de Ciencias Genómicas, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.ORCID 0000-0001-8827-023X
Víctor H BustamanteDepartamento de Microbiología Molecular, Instituto de Biotecnología, Universidad Nacional Autónoma de México, Cuernavaca, Morelos, México.ORCID 0000-0002-8852-150X

Funding

Consejo Nacional de Ciencia y Tecnología CF-2019-373914Consejo Nacional de Ciencia y Tecnología CF-2023-I-425Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México CJTC/CTTC/1368/2024Dirección General de Asuntos del Personal Académico, Universidad Nacional Autónoma de México IG200224
6 · The paper itself

Abstract

Antimicrobial peptides (AMPs) are short chains of amino acids naturally produced by all kingdoms of life, which exhibit broad-spectrum activity against bacteria, fungi, and viruses and thus play a crucial defense role in organisms. Unlike conventional antibiotics, AMPs are less prone to induce bacterial resistance since they can act on multiple targets, mainly affecting cell membranes. Thus, AMPs are considered promising antibiotic agents for medical applications. However, bacteria have developed different mechanisms to resist the action of AMPs, which operate at the extracellular, surface, and intracellular levels. Extracellular defense against AMPs is mediated by an arsenal of molecules or cell-derived particles or structures that are secreted and constitute the bacterial releasome. The bacterial releasome-associated factors can sequester, degrade, or chemically modify AMPs, thus providing individual and collective bacterial defense against AMPs. This minireview describes how diverse and impressive the releasome mechanisms mediating AMPs resistance are as a first line of defense.

Indexed as

Anti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesBacteriaDrug Resistance, BacterialAnti-Bacterial AgentsAntimicrobial Cationic PeptidesAntimicrobial PeptidesAMPsantimicrobial peptidesbacterial defensebacterial resistanceextracellular defense

Identifiers

PMID40748075
PMCPMC12369334

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.